NSPR vs. LUNG, ELMD, ZYXI, DRTS, PROF, CATX, NYXH, SKIN, LAKE, and SGHT
Should you be buying InspireMD stock or one of its competitors? The main competitors of InspireMD include Pulmonx (LUNG), Electromed (ELMD), Zynex (ZYXI), Alpha Tau Medical (DRTS), Profound Medical (PROF), Perspective Therapeutics (CATX), Nyxoah (NYXH), Beauty Health (SKIN), Lakeland Industries (LAKE), and Sight Sciences (SGHT). These companies are all part of the "medical equipment" industry.
InspireMD vs.
Pulmonx (NASDAQ:LUNG) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk, community ranking and dividends.
Pulmonx presently has a consensus price target of $12.75, indicating a potential upside of 94.66%. InspireMD has a consensus price target of $4.75, indicating a potential upside of 75.28%. Given Pulmonx's higher probable upside, equities research analysts plainly believe Pulmonx is more favorable than InspireMD.
InspireMD has lower revenue, but higher earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.
Pulmonx has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500.
Pulmonx received 29 more outperform votes than InspireMD when rated by MarketBeat users. Likewise, 44.00% of users gave Pulmonx an outperform vote while only 4.82% of users gave InspireMD an outperform vote.
91.0% of Pulmonx shares are held by institutional investors. Comparatively, 44.8% of InspireMD shares are held by institutional investors. 5.7% of Pulmonx shares are held by company insiders. Comparatively, 29.7% of InspireMD shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Pulmonx has a net margin of -72.01% compared to InspireMD's net margin of -413.96%. Pulmonx's return on equity of -53.88% beat InspireMD's return on equity.
In the previous week, Pulmonx had 1 more articles in the media than InspireMD. MarketBeat recorded 1 mentions for Pulmonx and 0 mentions for InspireMD. InspireMD's average media sentiment score of 0.59 beat Pulmonx's score of 0.00 indicating that InspireMD is being referred to more favorably in the news media.
Summary
Pulmonx beats InspireMD on 10 of the 18 factors compared between the two stocks.
Get InspireMD News Delivered to You Automatically
Sign up to receive the latest news and ratings for NSPR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InspireMD Competitors List
Related Companies and Tools
This page (NYSE:NSPR) was last updated on 1/5/2025 by MarketBeat.com Staff
